Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 versus trastuzumab emtansine in HER2-positive advanced breast cancer
CTR20250049Phase 3Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab repodatecan in breast cancer, sponsored by Kanion Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20250049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250049.